AAPG
Income statement / Annual
Last year (2024), Ascentage Pharma Group International's total revenue was $980.65 M,
an increase of 341.77% from the previous year.
In 2024, Ascentage Pharma Group International's net income was -$405.43 M.
See Ascentage Pharma Group International,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$980.65 M |
$221.98 M |
$209.71 M |
$4.33 M |
$12.45 M |
$14.51 M |
$6.81 M |
$6.33 M |
$7.67 M |
| Cost of Revenue |
$29.09 M
|
$30.54 M
|
$22.00 M
|
$3.33 M
|
$1.97 M
|
$2.10 M
|
$0.00
|
$0.00
|
$261,000.00
|
| Gross Profit |
$951.57 M
|
$191.44 M
|
$187.71 M
|
$24.58 M
|
$10.48 M
|
$12.42 M
|
$6.81 M
|
$6.33 M
|
$7.41 M
|
| Gross Profit Ratio |
0.97
|
0.86
|
0.9
|
5.68
|
0.84
|
0.86
|
1
|
1
|
0.97
|
| Research and Development Expenses |
$947.25 M
|
$706.97 M
|
$743.10 M
|
$766.49 M
|
$564.57 M
|
$463.88 M
|
$249.57 M
|
$118.82 M
|
$102.69 M
|
| General & Administrative Expenses |
$187.13 M
|
$181.08 M
|
$170.60 M
|
$143.51 M
|
$62.69 M
|
$98.85 M
|
$89.72 M
|
$13.41 M
|
$17.71 M
|
| Selling & Marketing Expenses |
$196.00 M
|
$195.39 M
|
$157.42 M
|
$47.75 M
|
$1.37 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$383.12 M
|
$376.46 M
|
$328.02 M
|
$191.26 M
|
$64.06 M
|
$98.85 M
|
$12.64 M
|
$13.41 M
|
$17.71 M
|
| Other Expenses |
-$9.07 M
|
-$19.36 M
|
-$33.60 M
|
-$63.34 M
|
$45.80 M
|
$32.37 M
|
-$8.63 M
|
$4.78 M
|
$1.63 M
|
| Operating Expenses |
$1.32 B
|
$1.06 B
|
$1.04 B
|
$894.42 M
|
$674.43 M
|
$595.10 M
|
$330.65 M
|
$137.00 M
|
$122.03 M
|
| Cost And Expenses |
$1.35 B
|
$1.09 B
|
$1.06 B
|
$897.75 M
|
$676.39 M
|
$597.20 M
|
$330.65 M
|
$137.00 M
|
$122.29 M
|
| Interest Income |
$37.84 M
|
$4.57 M
|
$9.73 M
|
$7.11 M
|
$5.22 M
|
$12.91 M
|
$7.06 M
|
$304,000.00
|
$13,000.00
|
| Interest Expense |
$64.46 M
|
$96.06 M
|
$52.79 M
|
$16.73 M
|
$6.26 M
|
$4.27 M
|
$36.92 M
|
$57.94 M
|
$3.26 M
|
| Depreciation & Amortization |
$93.17 M
|
$93.20 M
|
$9.13 M
|
$4.39 M
|
$3.97 M
|
$3.83 M
|
$18.46 M
|
$12.50 M
|
$164,369.00
|
| EBITDA |
-$237.63 M |
-$743.61 M |
-$771.47 M |
-$787.19 M |
-$641.77 M |
-$1.45 B |
-$291.53 M |
-$49.68 M |
-$103.03 M |
| EBITDA Ratio |
-0.24
|
-3.35
|
-3.68
|
-181.9
|
-51.55
|
-100.02
|
-42.83
|
-7.85
|
-13.44
|
| Operating Income Ratio |
-0.38
|
-3.93
|
-4.05
|
-201
|
-53.33
|
-40.15
|
-7.38
|
-20.65
|
-14.95
|
| Total Other Income/Expenses Net |
-$25.53 M
|
-$60.23 M
|
-$37.36 M
|
$37.59 M
|
-$11.51 M
|
-$899.63 M
|
-$23.07 M
|
$10.55 M
|
$6.78 M
|
| Income Before Tax |
-$395.26 M
|
-$932.86 M
|
-$887.17 M
|
-$832.25 M
|
-$675.45 M
|
-$1.48 B
|
-$346.91 M
|
-$120.12 M
|
-$107.84 M
|
| Income Before Tax Ratio |
-0.4
|
-4.2
|
-4.23
|
-192.31
|
-54.25
|
-102.14
|
-50.96
|
-18.98
|
-14.07
|
| Income Tax Expense |
$10.43 M
|
-$7.15 M
|
-$4.25 M
|
-$49.83 M
|
$2.16 M
|
-$1.60 M
|
-$1.60 M
|
-$1.60 M
|
$0.00
|
| Net Income |
-$405.43 M
|
-$925.64 M
|
-$882.92 M
|
-$782.42 M
|
-$677.61 M
|
-$1.48 B
|
-$345.31 M
|
-$118.51 M
|
-$107.84 M
|
| Net Income Ratio |
-0.41
|
-4.17
|
-4.21
|
-180.8
|
-54.43
|
-102.03
|
-50.73
|
-18.73
|
-14.07
|
| EPS |
-0.746 |
-13.12 |
-13.4 |
-12.28 |
-12.56 |
-50.76 |
-6.67 |
-2.29 |
-2.08 |
| EPS Diluted |
-0.746 |
-13.12 |
-13.4 |
-12.28 |
-12.56 |
-50.76 |
-6.67 |
-2.29 |
-2.08 |
| Weighted Average Shares Out |
$75.52 M
|
$70.57 M
|
$65.92 M
|
$63.65 M
|
$53.98 M
|
$29.18 M
|
$51.77 M
|
$51.77 M
|
$51.77 M
|
| Weighted Average Shares Out Diluted |
$75.52 M
|
$70.57 M
|
$65.92 M
|
$63.65 M
|
$53.98 M
|
$29.18 M
|
$51.77 M
|
$51.77 M
|
$51.77 M
|
| Link |
|
|
|
|
|
|
|
|
|
